Vertex has the revenue power to excel during any market environment.

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

These biotech companies have catalysts ahead.

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers. The Food and Drug ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns ...